Journal of Cystic Fibrosis
Volume 4, Issue 4 , Pages 221-225 , December 2005

The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis

  • S. Glass

      Affiliations

    • Department of Respiratory Paediatrics, Freeman Hospital, Freeman Road, Heaton, Newcastle upon Tyne, England, NE7 7DN, UK
    • Corresponding Author InformationCorresponding author. Department of Paediatrics, Royal Bolton Hospital, Minerva Road, Farnworth, Bolton, Lancashire BL4 0JR, UK.
    • ,
  • N.D. Plant

      Affiliations

    • Department of Paediatric Nephrology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, England, NE1 4LP, UK
    • ,
  • D.A. Spencer

      Affiliations

    • Department of Respiratory Paediatrics, Freeman Hospital, Freeman Road, Heaton, Newcastle upon Tyne, England, NE7 7DN, UK

Received 3 March 2005 ,Revised 30 August 2005 ,Accepted 7 September 2005.

References 

  1. Kaloyanides GJ. Drug–phospholipid interactions. Ren Fail. 1992;14:351–358
  2. Abramowsky CR, Swinehart GL. The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity. Hum Pathol. 1982;13:934–939
  3. Kaloyanides GJ. Aminoglycoside nephrotoxicity. In:  Schrier R,  Gottschalk C editor. Diseases of the kidney. 5th ed.. Boston: Little Brown and Co.; 1992;p. 1131–1163
  4. Price RG. Urinary enzymes, nephrotoxicity and renal disease. Toxicology. 1982;23:99–134
  5. Kunin CM, Chesney RW, Craig WA, England AC, DeAngelis C. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease. Pediater. 1978;62:751–760
  6. Rowe DJF, Anthony F, Polak A, Shaw K, Ward CD, Watts GF. Retinol binding protein as a small molecular weight marker of renal tubular dysfunction in diabetes mellitus. Ann Clin Biochem. 1987;24:477–478
  7. Akbar A, Rees JH, Nyamugunduru G, English MW, Spencer DA, Weller PH. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr. 1999;88:783–785
  8. Prime DJ, Tune BM. The nephrotoxicity of antimicrobial drugs. In:  Moss AJ editors. Pediatrics Update. New York: Elsevier/North Holland; 1981;p. 265–285
  9. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediater. 1976;58:259–263
  10. Ring E, Erwa W, Zobel G. N-acetyl-beta-d-glucosaminidase (NAG) im Urin. Ein zusatzlicher Parameter zur Lokalisa-tionsdiagnostik eines Harnwegsinfekts. Monatsschr Kinderheilkd. 1989;137:280–283
  11. Steinkamp G, Lutge M, Wurster U, Schulz-Baldes JG, Grone HJ, Ehrich JH. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr. 1986;145:526–531
  12. De Broe ME, Giuliano RA, Verpooten GA. Aminoglycoside nephrotoxicity: mechanism and prevention. Adv Exp Med Biol. 1989;252:233–245
  13. Godson C, Ryan MP, O'Halloran D, Bourke S, Brady HR, FitzGerald MX. Investigation of aminoglycoside nephrotoxicity in cystic fibrosis patients. Scand J Gastroenterol Suppl. 1988;143:70–73
  14. Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-beta-d-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child. 1998;78:540–543
  15. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. TOPIC Study Group Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial. Lancet. 2005;365:573–578
  16. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–226

☆ The data were presented orally at the Royal College of Paediatrics and Child Health Meeting, York, England, 2003 and in poster form at the North American Cystic Fibrosis Conference, Anaheim, USA, 2003, appearing subsequently in the Conference proceedings (Pediatr Pulmonol Suppl 2003; 25: 326).

PII: S1569-1993(05)00118-9

doi: 10.1016/j.jcf.2005.09.003

Journal of Cystic Fibrosis
Volume 4, Issue 4 , Pages 221-225 , December 2005

Article Tools

* Image Usage & Resolution